AC0010

DRUG6 trials

Sponsors

Sun Yat-sen University, Hangzhou ACEA Pharmaceutical Research Co., Ltd.

Conditions

Carcinoma, Non-Small-Cell LungCarcinoma，Non-Small-Cell LungMetastatic Non-small Cell Lung CancerNSCLCNon-Small Cell Lung Cancer

Phase 1

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Advanced Non Small Cell Lung Cancer

Sun Yat-sen UniversityNon-Small Cell Lung Cancer

Start: 2014-09-30End: 2017-12-31Target: 100Updated: 2016-11-23

Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010 in Patients With EGFR T790M Positive NSCLC

Hangzhou ACEA Pharmaceutical Research Co., Ltd.Metastatic Non-small Cell Lung Cancer

Start: 2015-01-31End: 2023-03-31Updated: 2021-09-10

Study to Investigate the Absorption, Metabolism and Excretion of [14C] AC0010 in Patients With Advanced NSCLC

CompletedNCT03001609

Hangzhou ACEA Pharmaceutical Research Co., Ltd.Carcinoma, Non-Small-Cell Lung

Start: 2016-11-30End: 2017-09-30Updated: 2017-10-03

Preliminary Evaluation of Safety and Efficacy by [14C] AC0010 Trail and Subsequent AC0010 Treatment

CompletedNCT03053219

Hangzhou ACEA Pharmaceutical Research Co., Ltd.Carcinoma，Non-Small-Cell Lung

Start: 2016-11-30End: 2018-12-31Updated: 2019-02-01

Phase 2

Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC

Hangzhou ACEA Pharmaceutical Research Co., Ltd.Metastatic Non-small Cell Lung Cancer

Start: 2017-05-18End: 2020-12-17Target: 222Updated: 2019-02-19

Phase 3

A Study Comparing AC0010 and Chemotherapy in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKI

WithdrawnNCT03058094

Hangzhou ACEA Pharmaceutical Research Co., Ltd.NSCLC

Start: 2018-12-31End: 2020-01-31Updated: 2019-02-04

Related Papers

Safety and efficacy of abivertinib (AC0010), a third-generation EGFR tyrosine kinase inhibitor, in Chinese patients with EGFR-T790M positive non-small cell lung cancer (NCSLC).

Journal of Clinical Oncology2019-05-207 citations

Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial.

2019-04-2334 citations

Penetration of the blood-brain barrier by avitinib and its control of intra/extra-cranial disease in non-small cell lung cancer harboring the T790M mutation.

2018-05-2115 citations

The ability of avitinib to penetrate the blood brain barrier and its control of intra-/extra- cranial disease in patients of non-small cell lung cancer (NSCLC) harboring EGFR T790M mutation.

Journal of Clinical Oncology2017-05-207 citations